Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Covid-19: Synairgen embraces virtual clinical trials

Virtualised clinical trials have become more commonplace amid the Covid-19 pandemic as a mechanism through which pharma companies can avoid delaying or cancelling their trials. The standard approach from the industry has been to adapt traditional, existing studies, but Southampton-based Synairgen is taking a different approach. It has launched two trials of its IFN-beta drug for at-risk Covid-19 patients, one in hospital in severe patients and the second an at-home virtual trial in newly diagnosed patients.

Close
Close
Close

Go Top